These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 27692092)

  • 21. Identification of Borrelia burgdorferi ospC genotypes in canine tissue following tick infestation: implications for Lyme disease vaccine and diagnostic assay design.
    Rhodes DV; Earnhart CG; Mather TN; Meeus PF; Marconi RT
    Vet J; 2013 Nov; 198(2):412-8. PubMed ID: 23962611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination of horses with Lyme vaccines for dogs induces short-lasting antibody responses.
    Guarino C; Asbie S; Rohde J; Glaser A; Wagner B
    Vaccine; 2017 Jul; 35(33):4140-4147. PubMed ID: 28668566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and development of a novel vaccine for protection against Lyme borreliosis.
    Comstedt P; Hanner M; Schüler W; Meinke A; Lundberg U
    PLoS One; 2014; 9(11):e113294. PubMed ID: 25409015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reductions in human Lyme disease risk due to the effects of oral vaccination on tick-to-mouse and mouse-to-tick transmission.
    Voordouw MJ; Tupper H; Önder Ö; Devevey G; Graves CJ; Kemps BD; Brisson D
    Vector Borne Zoonotic Dis; 2013 Apr; 13(4):203-14. PubMed ID: 23428088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a multiplex assay for the detection of antibodies to Borrelia burgdorferi in horses and its validation using Bayesian and conventional statistical methods.
    Wagner B; Freer H; Rollins A; Erb HN; Lu Z; Gröhn Y
    Vet Immunol Immunopathol; 2011 Dec; 144(3-4):374-81. PubMed ID: 21890217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21.
    Coughlin RT; Fish D; Mather TN; Ma J; Pavia C; Bulger P
    J Infect Dis; 1995 Apr; 171(4):1049-52. PubMed ID: 7706788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lyme borreliosis vaccination: the facts, the challenge, the future.
    Schuijt TJ; Hovius JW; van der Poll T; van Dam AP; Fikrig E
    Trends Parasitol; 2011 Jan; 27(1):40-7. PubMed ID: 20594913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental infection of dogs with Borrelia burgdorferi sensu stricto using Ixodes scapularis ticks artificially infected by capillary feeding.
    Korshus JB; Munderloh UG; Bey RF; Kurtti TJ
    Med Microbiol Immunol; 2004 Feb; 193(1):27-34. PubMed ID: 12884036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testing of the Biocan B inj. ad us. vet. vaccine and development of the new recombinant vaccine against canine borreliosis.
    Tuhácková J; Bĕláková J; Krupka M; Neperený J; Chumela J; Weigl E; Vrzal V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):297-302. PubMed ID: 16601776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of sarolaner in the prevention of Borrelia burgdorferi and Anaplasma phagocytophilum transmission from infected Ixodes scapularis to dogs.
    Honsberger NA; Six RH; Heinz TJ; Weber A; Mahabir SP; Berg TC
    Vet Parasitol; 2016 May; 222():67-72. PubMed ID: 26906926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seroprevalence of Borrelia burgdorferi-specific C6 antibody in dogs before and after implementation of a nonadjuvanted recombinant outer surface protein A vaccine in a Rhode Island small animal clinic.
    Hebert D; Eschner A
    Vet Ther; 2010; 11(3):E1-9. PubMed ID: 20960414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
    Fawcett PT; Rose CD; Budd SM; Gibney KM
    Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
    Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
    J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination against Lyme disease: past, present, and future.
    Embers ME; Narasimhan S
    Front Cell Infect Microbiol; 2013; 3():6. PubMed ID: 23407755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ability of an oral formulation of afoxolaner to protect dogs from Borrelia burgdorferi infection transmitted by wild Ixodes scapularis ticks.
    Baker CF; McCall JW; McCall SD; Drag MD; Mitchell EB; Chester ST; Larsen D
    Comp Immunol Microbiol Infect Dis; 2016 Dec; 49():65-69. PubMed ID: 27865266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies.
    Kurtenbach K; Dizij A; Voet P; Hauser P; Simon MM
    Vaccine; 1997 Oct; 15(15):1670-4. PubMed ID: 9364698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi.
    Golde WT; Piesman J; Dolan MC; Kramer M; Hauser P; Lobet Y; Capiau C; Desmons P; Voet P; Dearwester D; Frantz JC
    Infect Immun; 1997 Mar; 65(3):882-9. PubMed ID: 9038292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
    Wressnigg N; Pöllabauer EM; Aichinger G; Portsmouth D; Löw-Baselli A; Fritsch S; Livey I; Crowe BA; Schwendinger M; Brühl P; Pilz A; Dvorak T; Singer J; Firth C; Luft B; Schmitt B; Zeitlinger M; Müller M; Kollaritsch H; Paulke-Korinek M; Esen M; Kremsner PG; Ehrlich HJ; Barrett PN
    Lancet Infect Dis; 2013 Aug; 13(8):680-9. PubMed ID: 23665341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study with a commercial vaccine against Lyme borreliosis in horses using two different vaccination schedules: Characterization of the humoral immune response.
    Knödlseder JM; Fell SF; Straubinger RK
    Vaccine; 2019 Nov; 37(49):7207-7212. PubMed ID: 31635975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunization of mice by recombinant OspA preparations and protection against Borrelia burgdorferi infection induced by Ixodes ricinus tick bites.
    Gern L; Rais O; Capiau C; Hauser P; Lobet Y; Simoen E; Voet P; Pêtre J
    Immunol Lett; 1994 Mar; 39(3):249-58. PubMed ID: 8034340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.